Glucotrack Announces Expansion Of Its Continuous Glucose Monitoring Technology To Epidural Glucose Monitoring
Glucotrack Announces Expansion Of Its Continuous Glucose Monitoring Technology To Epidural Glucose Monitoring
Expansion offers the potential for continuous, discreet and simplified epidural glucose monitoring solutions for patients with Painful Diabetic Neuropathy
擴張爲糖尿病痛性神經病患者提供持續、謹慎和簡化的硬膜外血糖監測解決方案提供了潛力
Rutherford, NJ, April 16, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it is expanding its glucose monitoring technology to include measuring glucose in the epidural space. A continuous glucose monitoring system that takes readings in the spinal epidural space may be integrated with existing treatments for patients with Painful Diabetic Neuropathy (PDN).
新澤西州盧瑟福，2024年4月16日（GLOBE NEWSWIRE）——專注於設計、開發和商業化糖尿病患者新技術的醫療器械公司Glucotrack, Inc.（納斯達克股票代碼：GCTK）（“Glucotrack” 或 “公司”）宣佈正在擴大其血糖監測技術，將硬膜外領域的血糖測量包括在內。在脊柱硬膜外空間進行讀數的連續血糖監測系統可以與糖尿病疼痛性神經病變（PDN）患者的現有治療方法相結合。
PDN is a progressive neurological disorder that affects approximately one-fifth of the more than 38 million Americans with with diabetes, equating to more than 7 million individuals.1,2 Its symptoms include pain and numbness in the feet, legs, and hands which can significantly impact patients' quality of life and functional ability.3 Recently, Spinal Cord Stimulation (SCS) technology has been indicated as a treatment option providing significant long-term pain relief to these patients.4 A spinal cord stimulator is an implanted device, with electrodes placed in the epidural space, that sends low levels of electricity directly into the spinal cord to relieve pain.5 Glucotrack's sensor has the potential to be integrated with existing SCS devices to measure epidural glucose in patients with PDN who are undergoing SCS treatment. Combining SCS and continuous glucose monitoring (CGM) could provide several possible advantages, such as simplifying device management for those patients.
PDN 是一種進行性神經系統疾病，在3,800多萬美國糖尿病患者中，約有五分之一受到影響，相當於超過700萬人。1,2 其症狀包括腳、腿部和手部疼痛和麻木，這可能會嚴重影響患者的生活質量和功能能力。3 最近，脊髓刺激（SCS）技術被列爲一種治療方案，可以顯著緩解這些患者的長期疼痛。4 A 臍帶刺激器是一種植入式設備，其電極放置在硬膜外空間，可將低水平的電量直接輸送到脊髓以緩解疼痛。5 Glucotrack 的傳感器有可能與現有的 SCS 設備集成，用於測量正在接受 SCS 治療的 PDN 患者的硬膜外血糖。將SCS和持續血糖監測（CGM）相結合可以提供多種可能的優勢，例如簡化這些患者的設備管理。
Glucotrack has successfully completed preclinical animal testing in an acute setting. Building on the success of the acute studies, the Company has now initiated a long-term animal study to assess sustained epidural glucose monitoring performance. This is the second application of Glucotrack's technology for implantable continuous glucose monitoring, in addition to its development of a long-term Continuous Blood Glucose Monitoring (CBGM) system.
Glucotrack已成功完成了急性環境的臨床前動物試驗。在急性研究成功的基礎上，該公司現已啓動一項長期動物研究，以評估持續的硬膜外血糖監測性能。這是Glucotrack技術在植入式持續血糖監測方面的第二次應用，此外還開發了長期持續血糖監測（CBGM）系統。
The preclinical testing compared the Glucotrack sensor against blood glucose and a commercially available subcutaneous CGM in an acute large animal model while varying blood glucose levels for several hours. The results demonstrated the Glucotrack epidural glucose values closely tracked both the blood glucose and subcutaneous CGM values. The study was completed with no adverse effect on the animals. A second acute study successfully confirmed the repeatability of these results.
臨床前測試將Glucotrack傳感器與血糖和急性大型動物模型中的市售皮下CGM進行了比較，同時血糖水平變化了幾個小時。結果表明，Glucotrack硬膜外葡萄糖值與血糖和皮下CGM值密切相關。該研究已完成，對動物沒有不良影響。第二項急性研究成功證實了這些結果的可重複性。
"We have always been committed to developing a portfolio of innovative glucose monitoring technologies to offer patients with diabetes more choice; today's announcement underscores this commitment." said Paul V. Goode, PhD, CEO of Glucotrack. "We are excited to pioneer the epidural glucose monitoring space which we believe holds meaningful strategic potential. By making disease management more intuitive and less intrusive, Glucotrack is looking beyond traditional approaches to improve the quality of life for millions of people with diabetes."
Glucotrack首席執行官保羅·古德博士說：“我們一直致力於開發一系列創新的血糖監測技術，爲糖尿病患者提供更多選擇；今天的公告強調了這一承諾。”“我們很高興開創硬膜外血糖監測領域，我們認爲該領域具有重要的戰略潛力。通過使疾病管理更加直觀，減少干擾，Glucotrack正在超越傳統方法，改善數百萬糖尿病患者的生活質量。”
譯文內容由第三人軟體翻譯。